UVA researchers Alban Gaultier (one of our Pharmacology Training Faculty) and Dorian Rosen (one of our Pharmacology Student Alumni) found last year that fluvoxamine may stop the deadly inflammation known as sepsis, in which the immune response spirals out of control. The drug, they determined, reduced the production of cytokines. It proved effective in mice as a preventative treatment for sepsis, and now it will be tested as a protective measure for patients with COVID-19.
- About
- Education
- Research
- Research Departments
- Research Offices
- Research Centers
- Cancer Center
- Cancer Research
- Cardiovascular Research Center
- Carter Immunology Center
- Center for Behavioral Health & Technology
- Center for Brain Immunology & Glia
- Center for Diabetes Technology
- Center for Immunity, Inflammation & Regenerative Medicine
- Center for Public Health Genomics
- Center for Membrane & Cell Physiology
- Center for Research in Reproduction
- Myles H. Thaler Center for AIDS & Human Retrovirus Research
- Child Health Research Center (Pediatrics)
- Division of Perceptual Studies
- Research News: The Making of Medicine
- Research Core Facilities
- Other Research Programs
- Policies & Guidelines
- Clinical
- Community
- Diversity
- News